{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:46:34Z","timestamp":1780479994684,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.3816\/ccc.2008.n.002","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:06:38Z","timestamp":1221080798000},"page":"7-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Triplet Combination of Fluoropyrimidines, Oxaliplatin, and Irinotecan in the First-Line Treatment of Metastatic Colorectal Cancer"],"prefix":"10.3816","volume":"7","author":[{"given":"Gianluca","family":"Masi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Vasile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Loupakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Allegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2008.n.002_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.bjc.6603233","article-title":"Management of advanced colorectal cancer: state of the art","volume":"95","author":"Saunders","year":"2006","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2008.n.002_bib2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1054\/bjoc.1999.1254","article-title":"Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomised con trolled trials","volume":"82","author":"Jonker","year":"2000","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2008.n.002_bib3","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.3816\/CCC.2008.n.002_bib4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2008.n.002_bib5","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1200\/JCO.2005.05.546","article-title":"Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986","volume":"23","author":"Kohne","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer","volume":"181","author":"Giacchetti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib7","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1023\/A:1008347829017","article-title":"Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery","volume":"10","author":"Giacchetti","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10434-001-0347-3","article-title":"Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal","volume":"8","author":"Adam","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib10","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/annonc\/mdh217","article-title":"Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients","volume":"15","author":"Pozzo","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib11","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdi246","article-title":"Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates","volume":"16","author":"Folprecht","year":"2005","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment","volume":"22","author":"Grothey","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1054\/bjoc.2000.1600","article-title":"Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines","volume":"84","author":"Fischel","year":"2001","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2008.n.002_bib15","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.2002.08.015","article-title":"Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial","volume":"20","author":"Souglakos","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/annonc\/mdg119","article-title":"An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin\/5-fluorouracil every 2 weeks in patients with advanced solid tumours","volume":"14","author":"Ychou","year":"2003","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib17","first-page":"104","article-title":"Irinotecan, oxaliplatin, and 5-fluorouracil\/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study","volume":"2","author":"Calvo","year":"2002","journal-title":"Clin Colorectal Cancer"},{"key":"10.3816\/CCC.2008.n.002_bib18","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/sj.bjc.6601382","article-title":"A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients","volume":"17","author":"Garufi","year":"2003","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2008.n.002_bib19","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/annonc\/mdf307","article-title":"Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies","volume":"13","author":"Comella","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib20","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1200\/JCO.2003.01.238","article-title":"Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumours","volume":"21","author":"Goetz","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib21","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2002.12.075","article-title":"Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer","volume":"20","author":"Falcone","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib22","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdh470","article-title":"First line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil\/leucovorin (FOLFOXIRI): results of phase II study with a simplified biweekly schedule","volume":"15","author":"Masi","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1245\/ASO.2006.03.094","article-title":"Treatment with 5-fluorouracil\/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer","volume":"13","author":"Masi","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib24","first-page":"273","article-title":"Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11\/L-OHP\/LV5FU (FOLFIRINOX): a prospective phase II trial","volume":"23","author":"Quenet","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/annonc\/mdl317","article-title":"Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil\/leucovorin in patients with untreated metastatic gastric adenocarcinoma","volume":"18","author":"Lee","year":"2007","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib26","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.2005.06.050","article-title":"Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer\u2014a Groupe Tumeurs Digestives of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer study","volume":"23","author":"Conroy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CCC.2008.n.002_bib27","first-page":"201s","article-title":"Randomized phase II trial comparing FOLFIRINOX (5FU\/leucovorin, irinotecan and oxaliplatin) vs gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. First results of the ACCORD 11\/0402 trial","volume":"25","author":"Ychou","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib28","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2002.04.123","article-title":"Multicenter phase III study of uracil\/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer","volume":"20","author":"Douillard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib29","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib30","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","article-title":"XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer","volume":"22","author":"Cassidy","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000079482","article-title":"First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer","volume":"66","author":"Park","year":"2004","journal-title":"Oncology"},{"key":"10.3816\/CCC.2008.n.002_bib32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.bjc.6603493","article-title":"Uracil\/ftorafur\/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study","volume":"96","author":"Bajetta","year":"2007","journal-title":"Br J Cancer"},{"issue":"18 suppl","key":"10.3816\/CCC.2008.n.002_bib33","first-page":"185s","article-title":"Encouraging results from a phase I study of capecitabine (X), irinotecan (I), and oxaliplatin (O) as first-line therapy in patients (pts) with advanced or metastatic colorectal cancer (mCRC): phase I study findings","volume":"25","author":"Maroun","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CCC.2008.n.002_bib34","first-page":"256s","article-title":"Phase I dose-finding study of capecitabine (X) with escalating irinotecan (I) and oxaliplatin (O) in patients (pts) with previously treated solid tumors","volume":"23","author":"Samantas","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib35","first-page":"154","article-title":"Phase I study of oxaliplatin (Ox), irinotecan (Irino), and capecitabine (Cape) in patients with solid tumors","volume":"23","author":"Krishnamurthi","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CCC.2008.n.002_bib36","first-page":"307s","article-title":"Phase II study of oxaliplatin, capecitabine, and irinotecan (OCI) in patients (pts) with previously untreated colorectal cancer (crc)","volume":"23","author":"Pavia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib37","unstructured":"Petrovic Z. Oxaliplatin plus irinotecan and capecitabine as second line chemotherapy in patients with advanced colorectal carcinoma. Presented at: the 2005 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, Florida. Abstract 271."},{"key":"10.3816\/CCC.2008.n.002_bib38","first-page":"S11","article-title":"COI regimen (capecitabine, oxaliplatin, irinotecan) as possible neoajuvant treatment in metastatic colorectal cancer patients","volume":"17","author":"Buzzoni","year":"2006","journal-title":"Ann Oncol"},{"issue":"18 suppl","key":"10.3816\/CCC.2008.n.002_bib39","first-page":"187s","article-title":"The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (mCRC): preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (GONO)","volume":"25","author":"Masi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.bjc.6603521","article-title":"Concurrent irinotecan, oxaliplatin, and UFT in first-line treatment of metastatic colorectal cancer: a phase I study","volume":"96","author":"Sheikh","year":"2007","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2008.n.002_bib41","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CCC.2008.n.002_bib42","first-page":"170s","article-title":"Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (mCRC)","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib43","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","volume":"94","author":"Souglakos","year":"2006","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2008.n.002_bib44","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/annonc\/mdl119","article-title":"First-line 5-fluorouracil\/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer","volume":"17","author":"Masi","year":"2006","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2008.n.002_bib45","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1200\/JCO.2005.07.113","article-title":"Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale","volume":"23","author":"Colucci","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811703929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811703929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:01:01Z","timestamp":1761519661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811703929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S1533002811703929"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2008.n.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triplet Combination of Fluoropyrimidines, Oxaliplatin, and Irinotecan in the First-Line Treatment of Metastatic Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2008.n.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}